We are live on ! Find out more
SKBI

SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI

Delisted

SKBI was delisted on the 18th of December, 2015.

Back to rankings

15 hedge funds and large institutions have $2.38M invested in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in 2015 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 6 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more capital invested

Capital invested by funds: $1.55M → $2.38M (+$837K)

0% more funds holding

Funds holding: 15 → 15 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

83% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 6

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
6
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$20.5K
2
Renaissance Technologies
Renaissance Technologies
New York
+$15.9K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$250K
2
RCM
Rotella Capital Management
Washington
-$61.3K
3
SIM
Spark Investment Management
New York
-$17.4K
4
Deutsche Bank
Deutsche Bank
Germany
-$5.47K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$3.89K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$999K -$250K -58,932 -19%
BIT
2
BlackRock Institutional Trust
California
$687K – – –
Royal Bank of Canada
3
Royal Bank of Canada
Ontario, Canada
$121K -$3.89K -918 -3%
BCM
4
Bridgeway Capital Management
Texas
$95K – – –
EGA
5
Eagle Global Advisors
Texas
$88K – – –
CAM
6
ClariVest Asset Management
California
$78K – – –
RCM
7
Rotella Capital Management
Washington
$70K -$61.3K -14,467 -45%
California Public Employees Retirement System
8
California Public Employees Retirement System
California
$70K – – –
SIM
9
Spark Investment Management
New York
$66K -$17.4K -4,100 -19%
Renaissance Technologies
10
Renaissance Technologies
New York
$62K +$15.9K +3,741 +31%
Creative Planning
11
Creative Planning
Kansas
$20K – – –
Morgan Stanley
12
Morgan Stanley
New York
$19K +$20.5K +4,841 New
Deutsche Bank
13
Deutsche Bank
Germany
$3K -$5.47K -1,291 -59%
TRCT
14
Tower Research Capital (TRC)
New York
$2K -$1.08K -255 -35%
KTC
15
Kistler-Tiffany Companies
Pennsylvania
$2K – – –
Citigroup
16
Citigroup
New York
– -$3K -818 Closed

SKBI Hedge Fund Activity: Q1 2015 in Review

15 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) for Q1 2015, worth a combined $2.38M — up 54% from $1.55M a quarter earlier.

Fund positioning in SKBI was balanced in Q1 2015: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 6 trimmed.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $20.5K. The largest seller was Sabby Management, cutting an estimated $250K.

  • 15 institutional investors held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) as of Q1 2015, unchanged from Q4 2014.
  • Funds reported $2.38M of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) stock for Q1 2015, up 54% quarter-over-quarter.
  • 1 fund opened new SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) positions in Q1 2015 and 1 closed out, a net change of 0 holders.
  • The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) buyer in Q1 2015 was Morgan Stanley, an estimated $20.5K added.
  • The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) seller in Q1 2015 was Sabby Management, an estimated $250K sold.

Based on aggregated 13F filings for Q1 2015.